Efficacy of a Multimodal Online Lifestyle Intervention for Depressive Symptoms and Quality of Life in Individuals With a History of Major Depressive Disorder

Background Main depressive dysfunction (MDD) is a posh bio-psycho-social syndrome that impacts thousands and thousands of people and is likely one of the main causes of impaired high quality of life (QOL). Along with the signs of despair and low temper, many people with MDD additionally endure from isolation with out the sense of a supportive, surrounding neighborhood. Given the challenges of treating people with MDD, social isolation and a scarcity of communal connection, this randomized managed trial was designed to find out the efficacy of a multimodal, on-line and community-based way of life intervention for enhancing depressive signs and QOL in people with a historical past of MDD. Supplies and strategies The examine enrolled 71 feminine or male individuals between the ages of 20 and 64 with a self-reported BMI between 18.four and 34.9 kg/mand a historical past of MDD.

People have been randomized to both take part in a 44-day multimodal, on-line, community-based way of life intervention or positioned on a wait listing the place they might full the intervention at a later date. The multimodal intervention concerned a self-directed studying program the place people have been guided to make way of life modifications together with adopting a whole-foods eating regimen, rising motion, and adopting stress administration and mindfulness practices. All individuals accomplished the 36-Merchandise Quick Type Well being Survey (SF-36), the Cleveland Clinic Heart for Useful Drugs’s Medical Signs Questionnaire (MSQ), and the Affected person Well being Questionnaire-9 (PHQ-9) earlier than and after the web program to evaluate health-related QOL, general symptom burden, and depressive symptom burden, respectively. Outcomes A complete of 37 individuals have been randomized to take part within the multimodal intervention with 26 finishing all three examine questionnaires at each examine time factors; 34 individuals have been randomized to the wait listing management group with 27 finishing all three examine questionnaires at each examine time factors.

There have been no clinically or statistically vital variations between the management group or the intervention group at baseline. The management group confirmed no clinically nor statistically vital modifications within the MSQ, PHQ-9 or any of the eight subdomains of the SF-36 from the start to the top of the 10-week examine interval. When in comparison with the management group, the intervention group confirmed statistically and clinically vital enhancements in median (M) scores of the SF-36 subdomains of vitality and psychological well being, and clinically however not statistically vital enhancements within the subdomain of emotional function functioning. There have been further statistically and clinically vital enhancements within the imply rating of the MSQ and M scores of the PHQ-9 (therapy pre-intervention M = 10.5, inter-quartile vary [IQR] = 14, to therapy post-intervention M = 5, IQR = 8.25; management pre-intervention M = 15, IQR = 8, to manage post-intervention M = 13.5, IQR = 12.5). Conclusions Our randomized managed examine gives proof for the function of a multimodal, on-line and community-based way of life intervention to enhance depressive signs, QOL, and whole symptom burden in people with a historical past of MDD. Given the rising challenges of successfully supporting people struggling with MDD, it seems vital to additional discover the utilization of novel, multimodal and self-directed way of life interventions.

 

Birjand longitudinal growing older examine (BLAS): the targets, examine protocol and design (wave I: baseline knowledge gathering)

Goals: The tempo of inhabitants growing older is rising quickly world wide. Growing older is related to the emergence of various well being standing together with geriatric syndrome akin to frailty, diabetes, cardiovascular illnesses, and dementia. These situations are essentially the most distinguished challenges for well being care programs and likewise aged individuals. Subsequently, understanding these modifications may help scientists to stop and deal with vital well being points and likewise enhance the useful skill of older adults.
Strategies: This can be a protocol of the primary wave of Birjand Longitudinal Growing older Research that’s an ongoing community-based potential cohort examine with a following up a minimum of 10 years. This examine carries out on aged inhabitants ≥ 60 years which have been residents in Birjand County (city and rural older topics). The choice of the individuals of this examine in city areas relies on an age group weighted multistage stratified random pattern whereas within the rural area the pattern was chosen from all ten rural areas of Birjand County by easy random sampling.
The agricultural area sampling was primarily based on the listing of the aged inhabitants which have been below the protection of the agricultural well being middle. Sociodemographic, previous medical historical past, way of life, sleep, actions of day by day dwelling, cognitive operate, high quality of life, and social capital have been evaluated by interviewing with the individuals and one of many informants. Anthropometric measures, electrocardiography, and interpretation of ophthalmologic examination have been carried out by specialists. Fasting Blood samples have been collected and bio-banked in – 80 °C. then lastly biochemical and hematologic markers have been measured.
Outcomes: That is the protocol of stage one baseline of Birjand Longitudinal Growing older Research (BLAS). The BLAS is an enjoining examine, the primary section of its baseline was carried out on a community- dwelling aged inhabitants pattern ≥ 60 years who have been residents in city and rural areas of Birjand County. This can be a neighborhood primarily based potential cohort examine with a minimum of 10 years observe up of individuals. The information for 65% of older topics (response price = 65%) that lived in clusters have been collected.
Conclusions: This examine may help scientists to acknowledge some threat components associated to the growing older course of and likewise conscious policymakers concerning the necessity to create heath care providers at regional and even nationwide ranges.
Efficacy of a Multimodal Online Lifestyle Intervention for Depressive Symptoms and Quality of Life in Individuals With a History of Major Depressive Disorder
Efficacy of a Multimodal Online Lifestyle Intervention for Depressive Symptoms and Quality of Life in Individuals With a History of Major Depressive Disorder

Identification and rating of essential bio-elements in drug-drug interplay by Market Basket Evaluation.

introduction: Drug-drug interactions (DDIs) are the primary causes of the opposed drug reactions and the character of the useful and molecular complexity of medicine habits within the human physique make DDIs onerous to stop and menace. With assistance from new applied sciences derived from mathematical and computational science, the DDI issues could be addressed with a minimal price and energy. The Market Basket Evaluation (MBA) is named a robust methodology for the identification of co-occurrence of issues for the invention of patterns and the frequency of the weather concerned.

Kappa Light chain Antibody

46588-100ul 100ul
EUR 252

Kappa light chain Antibody

DF13703 100ul
EUR 350

Kappa Light Chain (Kappa-IgLC) Antibody

abx411144-1mg 1 mg
EUR 551

Kappa Light Chain (Kappa-IgLC) Antibody

abx411421-1ml 1 ml
EUR 439

Kappa Light Chain (Kappa-IgLC) Antibody

abx411422-05mg 0.5 mg
EUR 662

Kappa Light Chain (Kappa-IgLC) Antibody

abx412052-1ml 1 ml
EUR 439

Kappa Light Chain (Kappa-IgLC) Antibody

abx413125-1mg 1 mg
EUR 829

Kappa Light Chain (Kappa-IgLC) Antibody

abx415783-1mg 1 mg
EUR 439

Kappa Light Chain (Kappa-IgLC) Antibody

abx415786-05mg 0.5 mg
EUR 398

Kappa Light Chain (Kappa-IgLC) Antibody

abx415797-1mg 1 mg
EUR 495

Kappa Light Chain (Kappa-IgLC) Antibody

abx415799-05mg 0.5 mg
EUR 398

Anti-Kappa Light Chain antibody

STJ16100959 100 tests
EUR 524

Anti-Kappa Light Chain antibody

STJ16101014 100 µg
EUR 354

Kappa Light Chain(L1C1) Antibody

BNC040018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF405S conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC040018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF405S conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC040264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF405S conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC040264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF405S conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC040681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF405S conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC040681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF405S conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC040709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), CF405S conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC040709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), CF405S conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC470018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF647 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC470018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF647 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC470264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF647 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC470264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF647 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC470681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF647 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC470681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF647 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC470709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), CF647 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC470709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), CF647 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC550018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF555 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC550018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF555 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC550264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF555 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC550264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF555 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNCAP0681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNCAP0681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNCAP0709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNCAP0709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNCB0018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), Biotin conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNCB0018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), Biotin conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNCB0264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), Biotin conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNCB0264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), Biotin conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNCB0681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), Biotin conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNCB0681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), Biotin conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNCB0709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), Biotin conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNCB0709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), Biotin conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC810018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF680R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC810018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF680R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC810264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF680R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC810264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF680R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC810681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF680R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC810681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF680R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC810709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), CF680R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC810709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), CF680R conjugate, Concentration: 0.1mg/mL

Ig kappa Light Chain Antibody

20-abx137077
  • EUR 356.00
  • EUR 523.00
  • 0.5 mg
  • 1 mg

kappa Light Chain (Free) Antibody

abx021500-1mg 1 mg
EUR 599

Kappa Light Chain(L1C1) Antibody

BNC700018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF770 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC700018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF770 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC700264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF770 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC700264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF770 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC700681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF770 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC700681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF770 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC700709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), CF770 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC700709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), CF770 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC880018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF488A conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC880018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF488A conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC880264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF488A conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC880264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF488A conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC880681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF488A conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC880681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF488A conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC880709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), CF488A conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC880709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), CF488A conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC940018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF594 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC940018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF594 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC940264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF594 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC940264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF594 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC940681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF594 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC940681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF594 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC610681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF660R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC610681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF660R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC610709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), CF660R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC610709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), CF660R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC680018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF568 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC680018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF568 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC680264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF568 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC680264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF568 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC680681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF568 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC680681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF568 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC680709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), CF568 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC680709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), CF568 conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNCA0018-250 250uL
EUR 383
Description: Primary antibody against Kappa Light Chain(L1C1), APC conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNCA0264-250 250uL
EUR 383
Description: Primary antibody against Kappa Light Chain(KLC264), APC conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNCA0681-250 250uL
EUR 383
Description: Primary antibody against Kappa Light Chain(HP6053), APC conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNCA0709-250 250uL
EUR 383
Description: Primary antibody against Kappa Light Chain(KLC709), APC conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNCAP0018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNCAP0018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNCAP0264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNCAP0264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNUM0018-50 50uL
EUR 395
Description: Primary antibody against Kappa Light Chain(L1C1), 1mg/mL

Kappa Light Chain(KLC264) Antibody

BNUM0264-50 50uL
EUR 395
Description: Primary antibody against Kappa Light Chain(KLC264), 1mg/mL

Kappa Light Chain(HP6053) Antibody

BNUM0681-50 50uL
EUR 395
Description: Primary antibody against Kappa Light Chain(HP6053), 1mg/mL

Kappa Light Chain(KLC709) Antibody

BNUM0709-50 50uL
EUR 395
Description: Primary antibody against Kappa Light Chain(KLC709), 1mg/mL

Kappa Light Chain(L1C1) Antibody

BNCP0018-250 250uL
EUR 383
Description: Primary antibody against Kappa Light Chain(L1C1), PerCP conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNCP0264-250 250uL
EUR 383
Description: Primary antibody against Kappa Light Chain(KLC264), PerCP conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNCP0681-250 250uL
EUR 383
Description: Primary antibody against Kappa Light Chain(HP6053), PerCP conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNCP0709-250 250uL
EUR 383
Description: Primary antibody against Kappa Light Chain(KLC709), PerCP conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC050018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF405M conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC050018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF405M conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC050264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF405M conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC050264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF405M conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC050681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF405M conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC050681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF405M conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC050709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), CF405M conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC050709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), CF405M conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC400018-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(L1C1), CF640R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(L1C1) Antibody

BNC400018-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(L1C1), CF640R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC400264-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC264), CF640R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC264) Antibody

BNC400264-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC264), CF640R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC400681-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(HP6053), CF640R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(HP6053) Antibody

BNC400681-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(HP6053), CF640R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC400709-100 100uL
EUR 199
Description: Primary antibody against Kappa Light Chain(KLC709), CF640R conjugate, Concentration: 0.1mg/mL

Kappa Light Chain(KLC709) Antibody

BNC400709-500 500uL
EUR 544
Description: Primary antibody against Kappa Light Chain(KLC709), CF640R conjugate, Concentration: 0.1mg/mL
Strategies: On this analysis, we used the MBA methodology to determine essential bio-elements within the incidence of DDIs. For this, we collected all identified DDIs from DrugBank. Then, the obtained knowledge have been analyzed by MBA methodology. All drug-enzyme, drug-carrier, drug-transporter and drug-target associations have been investigated. The extracted guidelines have been evaluated when it comes to the arrogance and assist to find out the significance of the extracted bio-elements.



Leave a Reply

Your email address will not be published.